Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JAMA Editorial Praises MIRACLE ICD Study, Calls For More Substudies

This article was originally published in The Gray Sheet

Executive Summary

An editorial by a Johns Hopkins physician in the May 28 Journal of the American Medical Association lends support to a growing number of electrophysiologists who have called on manufacturers to develop improved leads and guiding systems for cardiac resynchronization technology

You may also be interested in...



Medtronic MIRACLE

NYHA Class II heart failure patients appear to benefit from cardiac resynchronization therapy devices, according to results from Medtronic's MIRACLE ICD-II study, published in the Nov. 2 issue of Circulation. The 168-patient study showed that Class II patients treated with CRT-D devices exhibited a 58% improvement in a composite clinical endpoint at six months, compared with 36% for control patients, who received a CRT-D device with the CRT pacing function turned off. The company plans to combine the MIRACLE ICD-II study with data from other CRT studies, including the ongoing 500-patient REVERSE study, to expand the FDA-approved indication for CRT devices to include Class II patients. Class II represents about 2 mil. patients in the U.S. and 40% of all heart failure patients. Currently, CRT therapy is approved for Class III and IV patients (1"The Gray Sheet" June 2, 2003, p. 11)...

Medtronic MIRACLE

NYHA Class II heart failure patients appear to benefit from cardiac resynchronization therapy devices, according to results from Medtronic's MIRACLE ICD-II study, published in the Nov. 2 issue of Circulation. The 168-patient study showed that Class II patients treated with CRT-D devices exhibited a 58% improvement in a composite clinical endpoint at six months, compared with 36% for control patients, who received a CRT-D device with the CRT pacing function turned off. The company plans to combine the MIRACLE ICD-II study with data from other CRT studies, including the ongoing 500-patient REVERSE study, to expand the FDA-approved indication for CRT devices to include Class II patients. Class II represents about 2 mil. patients in the U.S. and 40% of all heart failure patients. Currently, CRT therapy is approved for Class III and IV patients (1"The Gray Sheet" June 2, 2003, p. 11)...

St. Jude Adds QuickSite Lead, “V-to-V” Pacing To RHYTHM Epic HF Trial

St. Jude expects its Epic HF ICD cardiac therapy (CRT) device to be approved in the U.S. with "V-to-V" pacing capability at about the same time as competitors Guidant and Medtronic add the indication to their CRT ICDs

Related Content

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel